Cost-effectiveness analysis of whole-mount pathology processing for patients with early breast cancer undergoing breast conservation.
暂无分享,去创建一个
M. Yaffe | C. Holloway | G. Clarke | N. Hong
[1] M. Yaffe,et al. Whole‐mount pathology of breast lumpectomy specimens improves detection of tumour margins and focality , 2016, Histopathology.
[2] M. Yaffe,et al. Tumor shrinkage associated with whole-mount histopathologic techniques in oral tongue carcinoma. , 2015, Pathology, research and practice.
[3] C. Earle,et al. Health system costs for stage-specific breast cancer: a population-based approach. , 2014, Current oncology.
[4] T. Bramley,et al. Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis , 2014, SpringerPlus.
[5] T. To,et al. Twenty-Five–Year Follow-up for Breast Cancer Incidence and Mortality of the Canadian National Breast Screening Study: Randomized Screening Trial , 2014 .
[6] T. To,et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial , 2014, BMJ : British Medical Journal.
[7] Seema A Khan,et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Macaskill,et al. The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast-Conserving Therapy: A Meta-Analysis , 2014, Annals of Surgical Oncology.
[9] Kela Liu,et al. A novel, automated technology for multiplex biomarker imaging and application to breast cancer , 2014, Histopathology.
[10] M. J. Yaffe,et al. 3D Pathology Volumetric Technique: A Method for Calculating Breast Tumour Volume from Whole-Mount Serial Section Images , 2012, International journal of breast cancer.
[11] S. Peacock,et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. , 2012, The oncologist.
[12] H. Feigelson,et al. Variability in reexcision following breast conservation surgery. , 2012, JAMA.
[13] J. Landercasper,et al. Variability in Reexcision Following Breast Conservation Surgery: McCahill LE, Single RM, Aiello Bowles EJ, et al (Michigan State Univ, Grand Rapids; Univ of Vermont, Burlington; Group Health Res Inst, Seattle, WA; et al) JAMA 307:467-475, 2012§ , 2012 .
[14] B. Luce,et al. Willingness to Pay for Cancer Prevention , 2012, PharmacoEconomics.
[15] S. J. Whitehead,et al. Health outcomes in economic evaluation: the QALY and utilities. , 2010, British medical bulletin.
[16] S. Bae,et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? , 2010, Health economics.
[17] Dan Wang,et al. An improved processing method for breast whole-mount serial sections for three-dimensional histopathology imaging. , 2009, American journal of clinical pathology.
[18] F. Fitzal. Consensus conference on breast conservation. , 2008, Journal of the American College of Surgeons.
[19] Angela Mariotto,et al. Cost of care for elderly cancer patients in the United States. , 2008, Journal of the National Cancer Institute.
[20] M. Rezai,et al. Breast-Conserving Treatment of Breast Cancer – Oncological and Reconstructive Aspects , 2008, Gynäkologisch-geburtshilfliche Rundschau.
[21] Gina M Clarke,et al. Spatial resolution requirements for acquisition of the virtual screening slide for digital whole-specimen breast histopathology. , 2007, Human pathology.
[22] L. Newman,et al. Complications in breast surgery. , 2007, Surgical Clinics of North America.
[23] M J Yaffe,et al. Whole‐specimen histopathology: a method to produce whole‐mount breast serial sections for 3‐D digital histopathology imaging , 2007, Histopathology.
[24] M. Rossing,et al. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.
[25] R. Mansel,et al. Consensus conference on breast conservation. , 2006, Journal of the American College of Surgeons.
[26] Elisabeth Fenwick,et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation , 2006, BMC Health Services Research.
[27] W. Dooley,et al. Understanding the mechanisms creating false positive lumpectomy margins. , 2005, American journal of surgery.
[28] F. Vicini,et al. Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy. A clinicopathologic study of 607 neoplasms from 583 patients. , 2003, American journal of clinical pathology.
[29] James K. Hammitt,et al. Effects of Disease Type and Latency on the Value of Mortality Risk , 2003 .
[30] Peter A Ubel,et al. What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.
[31] L. Layfield,et al. Utility of Four‐Quadrant Random Sections in Mastectomy Specimens , 2003, The breast journal.
[32] H. Safaii,et al. The pancake phenomenon contributes to the inaccuracy of margin assessment in patients with breast cancer. , 2002, American journal of surgery.
[33] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[34] P J Neumann,et al. Systematic overview of cost-utility assessments in oncology. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Tammy O. Tengs,et al. One thousand health-related quality-of-life estimates. , 2000, Medical care.
[36] C. Bell,et al. Are pharmaceuticals cost-effective? A review of the evidence. , 2000, Health affairs.
[37] E. Wiley,et al. Diagnostic discrepancies in breast specimens subjected to gross reexamination. , 1999, The American journal of surgical pathology.
[38] Geoff Delaney M.B.B.S.,et al. Predictors of local recurrence after treatment of ductal carcinoma in situ - A meta-analysis , 1999 .
[39] J. Boyages,et al. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. , 1999, Cancer.
[40] John Mullahy,et al. Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis , 1998 .
[41] E. P. Dellinger,et al. Perioperative antibiotic prophylaxis and wound infection following breast surgery. , 1993, The Journal of antimicrobial chemotherapy.
[42] A S Detsky,et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[43] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.